Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Nextech Venture, operating under the brand Nextech Invest, is a Zurich-based global venture capital firm founded in 1998. The firm focuses on oncology and oncology-adjacent therapeutics, diagnostics, and medical devices. Established by a team of leading oncology academics, Nextech Venture has built a strong scientific foundation and a robust network in the field. The firm manages and advises the first worldwide oncology-dedicated fund, which was launched in late 2006. This pioneering fund has positioned Nextech as a leader in oncology investments.
Currently, Nextech Venture operates with affiliate offices in Boston and San Francisco, expanding its reach and influence in the North American market. The firm manages a total of eight funds, with a portfolio comprising 108 investments. This extensive portfolio reflects Nextech's commitment to advancing cancer treatment through strategic investments in innovative companies.
Nextech Venture invests exclusively in companies involved in drug discovery, diagnostics, and medical devices that target oncology and related diseases. The firm typically invests in Series A and Growth Equity stages, with check sizes ranging from CHF 1M to 5M (approximately $1.1M to $5.5M). Their investment strategy emphasizes a comprehensive approach, supporting ventures from the discovery phase through clinical development.
The firm seeks companies that demonstrate preclinical animal model data showing efficacy or device prototypes that meet specific requirements. Nextech Venture's focus on oncology therapeutics and adjacent disease areas allows them to leverage their extensive scientific network and expertise in the oncology landscape, ensuring that their portfolio companies receive the necessary support to advance their innovations.
Nextech Venture has made 108 investments in various oncology-focused companies, contributing significantly to advancements in therapeutics and diagnostics. The portfolio includes a diverse range of innovative firms that are making strides in cancer treatment. Some notable companies in their portfolio include:
This diverse portfolio reflects Nextech's commitment to supporting companies that are at the forefront of cancer research and treatment.
Alfred Scheidegger - Managing Partner. Alfred has extensive experience in venture capital and oncology, having co-founded Nextech Venture. He has led numerous successful investments in the oncology sector and is known for his deep understanding of the scientific landscape.
David Livingston - Founding Scientific Advisory Board Member. David is affiliated with the Dana Farber Cancer Institute and has played a crucial role in shaping Nextech's scientific strategy since its inception.
As of March 2026, Nextech Venture continues to be active in the oncology investment space, managing a total of eight funds, including the first worldwide oncology-dedicated fund launched in 2006. The firm has made significant investments in various oncology-focused companies, contributing to advancements in therapeutics and diagnostics.
While there has been no recent public blog activity, Nextech's ongoing commitment to oncology innovation remains evident through its portfolio and investment strategy.
What are Nextech Venture's investment criteria?
Nextech Venture focuses on companies involved in oncology therapeutics, diagnostics, and medical devices. They typically invest in Series A and Growth Equity stages, looking for preclinical animal model data demonstrating efficacy or device prototypes that meet specific requirements.
How can I pitch to Nextech Venture?
Founders interested in pitching to Nextech Venture should prepare a detailed presentation that outlines their business model, market opportunity, and scientific data supporting their product. While specific application channels are not disclosed, a warm introduction through their network may enhance the chances of engagement.
What makes Nextech Venture different from other VC firms?
Nextech Venture is distinguished by its exclusive focus on oncology and its strong scientific foundation. The firm was the first to launch a worldwide oncology-dedicated fund in 2006, which underscores its commitment to advancing cancer treatment through strategic investments.
What is the geographic focus of Nextech Venture?
Nextech Venture invests globally, with a particular emphasis on North America and Europe. Their affiliate offices in Boston and San Francisco allow them to tap into key markets for oncology innovation.
What kind of support does Nextech Venture provide to portfolio companies?
Nextech Venture adds value through its extensive scientific network, access to leading oncology experts, and strategic guidance throughout the development process. This support spans from preclinical stages to clinical trials, ensuring that portfolio companies are well-positioned for success.
What is the typical check size for investments?
Nextech Venture typically invests between CHF 1M and 5M (approximately $1.1M to $5.5M) per financing round, aligning their investment strategy with the needs of early-stage and growth-stage companies in the oncology sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.